These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36918752)

  • 21. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab.
    Talbot J; Stuckey R; Wood N; Gordon A; Crossingham G; Weatherby S
    Eur J Hosp Pharm; 2024 Jan; ():. PubMed ID: 38182276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
    J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies - insights from the German NeuroTransData registry.
    Hong JB; Israel-Willner H; Peikert A; Schanbacher P; Tozzi V; Köchling M; Reuter U; Raffaelli B;
    J Headache Pain; 2024 Jun; 25(1):90. PubMed ID: 38825722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
    Barbanti P; Aurilia C; Egeo G; Proietti S; Torelli P; d'Onofrio F; Carnevale A; Tavani S; Orlando B; Fiorentini G; Colombo B; Filippi M; Bonassi S; Cevoli S;
    J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
    Muñoz-Vendrell A; Campoy S; Caronna E; Alpuente A; Torres-Ferrus M; Nieves Castellanos C; Olivier M; Campdelacreu J; Prat J; Camiña Muñiz J; Molina Martínez FJ; Mínguez-Olaondo A; Ruibal Salgado M; Santos Lasaosa S; Navarro Pérez MP; Morollón N; López Bravo A; Cano Sánchez LM; García-Sánchez SM; García-Ull J; Rubio-Flores L; Gonzalez-Martinez A; Quintas S; Echavarría Íñiguez A; Gil Luque S; Castro-Sánchez MV; Adell Ortega V; García Alhama J; Berrocal-Izquierdo N; Belvís R; Díaz-Insa S; Pozo-Rosich P; Huerta-Villanueva M
    J Headache Pain; 2023 Jun; 24(1):63. PubMed ID: 37268904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway improve the effectiveness of acute medication-a real-world study.
    Rosignoli C; Caponnetto V; Onofri A; Trozzi V; Tartaglione L; Silvestro M; Russo A; Sacco S; Ornello R
    Neurol Sci; 2024 Jul; 45(7):3305-3312. PubMed ID: 38340218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study.
    Cresta E; Bellotti A; Rinaldi G; Corbelli I; Sarchielli P
    CNS Neurosci Ther; 2024 Feb; 30(2):e14595. PubMed ID: 38332541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
    Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Giné-Ciprés E; Pozo-Rosich P
    Cephalalgia; 2024 Feb; 44(2):3331024231222923. PubMed ID: 38307497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents.
    Greene KA; Gentile CP; Szperka CL; Yonker M; Gelfand AA; Grimes B; Irwin SL
    Pediatr Neurol; 2021 Jan; 114():62-67. PubMed ID: 33232919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.
    Raffaelli B; Terhart M; Overeem LH; Mecklenburg J; Neeb L; Steinicke M; Reuter U
    Cephalalgia; 2022 Apr; 42(4-5):326-334. PubMed ID: 34579559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study.
    Russo CV; Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R
    Cephalalgia; 2023 Apr; 43(4):3331024231161809. PubMed ID: 36946234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies.
    Ferreira VL; Mainka FF; Wiens A; Pontarolo R
    Clin Drug Investig; 2023 Sep; 43(9):669-680. PubMed ID: 37665501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
    Caronna E; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    J Headache Pain; 2021 Oct; 22(1):120. PubMed ID: 34620085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study.
    Gonzalez-Martinez A; Pagán J; Sanz-García A; García-Azorín D; Rodríguez-Vico JS; Jaimes A; García AG; de Terán JD; González-García N; Quintas S; Belascoaín R; Casas Limón J; Latorre G; Calle de Miguel C; Sierra Á; Guerrero-Peral ÁL; Trevino-Peinado C; Gago-Veiga AB
    Eur J Neurol; 2022 Oct; 29(10):3102-3111. PubMed ID: 35726393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
    Caponnetto V; Russo A; Silvestro M; Tessitore A; De Icco R; Vaghi G; Sances G; Tassorelli C; Baraldi C; Castro FL; Guerzoni S; Prudenzano MP; Fallacara A; Gentile M; Ornello R; Onofri A; Burgalassi A; Chiarugi A; De Cesaris F; Granato A; Casalena A; De Tommaso M; Mampreso E; Merlo P; Coppola G; Battistini S; Rebecchi V; Rainero I; Sepe FN; Dalla Volta G; Sacco S; Geppetti P; Iannone LF;
    CNS Drugs; 2023 Dec; 37(12):1069-1080. PubMed ID: 37999868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series.
    Kaltseis K; Filippi V; Frank F; Eckhardt C; Schiefecker A; Broessner G
    BMC Neurol; 2023 Apr; 23(1):174. PubMed ID: 37118682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
    Pensato U; Baraldi C; Favoni V; Mascarella D; Matteo E; Andrini G; Cainazzo MM; Cortelli P; Pierangeli G; Guerzoni S; Cevoli S
    Cephalalgia; 2022 Jun; 42(7):645-653. PubMed ID: 35135357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.